Roche has pledged to work to reverse NICE’s preliminary decision this week that its spinal muscular atrophy (SMA) treatment, Evrysdi (risdiplam), should not be made available to patients on England’s National Health Service because it is too expensive.
In draft guidance published by the health technology assessment (HTA) body, NICE said that while it agreed that the...








